London, UK / Berlin, Germany. June 2nd, 2021 – Global Pricing Innovations, leading provider of pharma pricing insights, has joined Datarade, the fastest-growing data marketplace. Datarade’s tens of thousands of data buyers from every industry can now effortlessly discover, compare, and get access…
Sam Fieldwick joins GPI, as part of the Commercial Development team GPI are pleased to announce and welcome Sam Fieldwick as the new Commercial Development Manager. Sam will be responsible for working with existing and new clients, driving revenue for GPI and the…
London, UK., April 28, 2021 – Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced a strategic life sciences industry partnership with Global Pricing Innovations (GPI), a market leader in analytics, insights and innovative solutions that help life…
London, UK., April 28, 2021 – Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced a strategic life sciences industry partnership with Global Pricing Innovations (GPI), a market leader in analytics, insights and innovative solutions that help life…
The news comes as during the COVID-19 pandemic, women have lost their jobs or left the labour force in greater numbers than men. JP Morgan have a long standing commitment to supporting and promoting female-powered businesses, and this report highlights the changes we…
Thursday 15th April, 2021 – Global Pricing Innovations (GPI), announce innovative solution to empower insightful decision-making for the BioPharma industry. GPI pulse™ 2.0 launches, providing a more intuitive and powerful analytics platform. The pace of drug development is rapidly accelerating with the rise…
The French state-industry drug framework agreement stipulates that innovative products manufactured in the country can have the same initial price as the highest one applied in Germany, the UK, Italy, or Spain. The new 2021-24 framework agreement signed on Friday 5th March between…
Recently Spain’s medicines regulatory bodies announced the requirement of additional “economic evaluation” data for therapeutics positioning reports (IPTs) which is the equivalent of a Health Technology Assessment process in the country. This change is part of a revolution of the overall HTA process…
PFIZER AND BIONTECH HAVE PRODUCED BETTER THAN EXPECTED EFFICACY RESULTS BUT WILL AWAIT FOR SAFETY DATA BEFORE FILING LATER THIS MONTH. THE PHIII INTERIM ANALYSIS FINDS VACCINE 90% EFFECTIVE WITH EUA FILING EXPECTED LATE NOVEMBER. Pfizer and BioNTech have announced positive interim Phase…
Blogpost by Dimitra Sotou, MIHP, Client Solutions Lead, GPI Canada is due to adjust its international reference pricing (#IRP) basket of comparator countries come January, the 1st, 2021. The change was announced by the PMPRB in the final version of new guidelines; after five years…
Blogpost created by Dimitra S. Sotou, Client Solutions Lead, Pricing & Market Access As opposed to the rest of key EU payers focusing on cost containment strategies for 2021, the German umbrella payer group GKV-Spitzenverband (GKV-SV) has announced to be targeting a +4.6%…
The White House has blocked stricter Food and Drug Administration (FDA) guidelines for the emergency release of the coronavirus vaccine, that would have likely prevented its approval before next month’s presidential election. The new FDA guidelines were submitted for approval to the Office…
Spending Changes Recently the French government has published its Social Security Finance Bill 2021 (PLFSS 2021), which covers the annual review of their health and social security expenditure. With the impact of COVID-19 increasing there seems to be an ever-increasing cost cutting exercise…
By Musa Kureshy, Business Development Manager The impact of COVID-19 has been felt by every country and industry and the Netherlands was no exception. COVID-19 impactied drug manufacturing in China leading to it coming to a stand still and India implemented export restrictions…
News summarised by Dimitra S. Sotou, Sr. Consultant, Pricing & Market Access ”Sputnik V” On Tuesday, President Vladimir Putin, announced that Russia is the first nation in the world to grant approval to a coronavirus vaccine. The approval has been granted, despite the…
By Tom Brockbank, Senior Consultant, Pricing & Market Access Germany’s major payer AOK announces discount agreements and drug manufacturer incentives to ensure a stable supply chain throughout the COVID-19 pandemic AOK has announced two-year discount agreements for 119 drugs and an obligation for…
AUTHORS: Barkauskaite E, Patel P Beginning of the week and Day 1 for ISPOR Virtual 2020 today – We are very excited to share more results from our extensive R&D work. The infographic below provides a summary of the results of an indication…
AUTHORS: Sotou D, Barkauskaite E, Patel P Despite the worldwide impact due to COVID-19 pandemic, GPI continues to invest on extensive R&D work leading the way on how data can be leveraged to ensure our partners stay ahead of the curve. We are…
We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…
At the end of 2019, important legislative changes took place in the United States that could impact the country’s pharmaceutical industry over the coming years. The U.S. House of Representatives has passed the Lower Drug Costs Now Act on 12th December 2019, setting…
By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…
Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…
Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…
Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…
London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…
In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…
Last week, the result of negotiations between pharma companies and China’s National Healthcare Security administration was revealed. 150 medicines were evaluated, and the outcome is as follows. Out of the 119 new medicines evaluated, 70 were accepted onto the National Reimbursement Drug List…
Preeti Patel, the CEO of GPI, was invited to the Good Growth Summit, an event designed to inspire and connect female entrepreneurs across the US and UK tech ecosystem. The Summit took part at the St James’s Palace and was hosted by Princess…
This week, GPI had the pleasure to be invited to the Silicon Valley Comes to the UK (SVC2UK) summit. SVC2UK is an annual tech conference that brings world-leading tech entrepreneurs and investors to the UK for a series of workshops, panel discussions and…
Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…
BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…
In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…
Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…
On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…
President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…
Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…
Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…
New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…
Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…
International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape…
Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab…
Legal questions around the “Mischpreis” pricing approach are still hanging over sickness funds and manufacturers in Germany. The current price setting methodology as part of AMNOG negotiations take average weighted prices and considers the value and price potential across all indications and patient…
